These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 20304805)

  • 41. Thrombopoietin is required for full phenotype expression in a JAK2V617F transgenic mouse model of polycythemia vera.
    Spivak JL; Merchant A; Williams DM; Rogers O; Zhao W; Duffield A; Resar LS; Moliterno AR; Zhao ZJ
    PLoS One; 2020; 15(6):e0232801. PubMed ID: 32479500
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Polymorphisms in LNK Gene Correlated to the Clinical Type of Myeloproliferative Neoplasms.
    Chen Y; Fang F; Hu Y; Liu Q; Bu D; Tan M; Wu L; Zhu P
    PLoS One; 2016; 11(4):e0154183. PubMed ID: 27111338
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms.
    Ojeda MJ; Bragós IM; Calvo KL; Williams GM; Carbonell MM; Pratti AF
    Hematology; 2018 May; 23(4):208-211. PubMed ID: 28990497
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The first international meeting on V617F JAK2 mutation and its relevance in Philadelphia-negative myeloproliferative disorders.
    Kiladjian JJ; Casadevall N; Vainchenker W; Fenaux P
    Pathol Biol (Paris); 2007 Mar; 55(2):85-7. PubMed ID: 16901656
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms.
    Olcaydu D; Harutyunyan A; Jäger R; Berg T; Gisslinger B; Pabinger I; Gisslinger H; Kralovics R
    Nat Genet; 2009 Apr; 41(4):450-4. PubMed ID: 19287385
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The revised WHO diagnostic criteria for Ph-negative myeloproliferative diseases are not appropriate for the diagnostic screening of childhood polycythemia vera and essential thrombocythemia.
    Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Leone G; Foà R; Larocca LM
    Blood; 2007 Nov; 110(9):3384-6. PubMed ID: 17644735
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of the JAK2-V617F gene mutation in Turkish patients with essential thrombocythemia and polycythemia vera.
    Karkucak M; Yakut T; Ozkocaman V; Ozkalemkas F; Ali R; Bayram M; Gorukmez O; Ocakoglu G
    Mol Biol Rep; 2012 Sep; 39(9):8663-7. PubMed ID: 22722988
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The G allele of the JAK2 rs10974944 SNP, part of JAK2 46/1 haplotype, is strongly associated with JAK2 V617F-positive myeloproliferative neoplasms.
    Trifa AP; Cucuianu A; Petrov L; Urian L; Militaru MS; Dima D; Pop IV; Popp RA
    Ann Hematol; 2010 Oct; 89(10):979-83. PubMed ID: 20422415
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The JAK2 46/1 haplotype is a risk factor for myeloproliferative neoplasms in Chinese patients.
    Zhang X; Hu T; Wu Z; Kang Z; Liu W; Guan M
    Int J Hematol; 2012 Nov; 96(5):611-6. PubMed ID: 23054641
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Skewed ratio between type 1 and type 2 calreticulin mutations in essential thrombocytosis patients with concomitant Janus kinase 2 V617F mutation.
    Haunstrup LM; Ebbesen LH; Hansen M; Severinsen MT; Aggerholm A
    Exp Hematol; 2018 Dec; 68():62-65. PubMed ID: 30292681
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis.
    Boyd EM; Bench AJ; Goday-Fernández A; Anand S; Vaghela KJ; Beer P; Scott MA; Bareford D; Green AR; Huntly B; Erber WN
    Br J Haematol; 2010 Apr; 149(2):250-7. PubMed ID: 20151976
    [TBL] [Abstract][Full Text] [Related]  

  • 53. JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.
    Kilpivaara O; Levine RL
    Leukemia; 2008 Oct; 22(10):1813-7. PubMed ID: 18754026
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.
    Al Assaf C; Van Obbergh F; Billiet J; Lierman E; Devos T; Graux C; Hervent AS; Emmerechts J; Tousseyn T; De Paepe P; Papadopoulos P; Michaux L; Vandenberghe P
    Haematologica; 2015 Jul; 100(7):893-7. PubMed ID: 25934766
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Analysis of JAK2V617F mutation in Jordanian patients with myeloproliferative neoplasms.
    Jaradat SA; Khasawneh R; Kamal N; Matalka I; Al-Bishtawi M; Al-Sweedan S; Ayesh MH
    Hematol Oncol Stem Cell Ther; 2015 Dec; 8(4):160-6. PubMed ID: 26256826
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Complex molecular genetic algorithm in the diagnosis of myeloproliferative neoplasms].
    Krähling T; Balassa K; Meggyesi N; Bors A; Csomor J; Bátai Á; Halm G; Egyed M; Fekete S; Reményi P; Masszi T; Tordai A; Andrikovics H
    Orv Hetil; 2014 Dec; 155(52):2074-81. PubMed ID: 25528320
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of the prevalence and prospective clinical impact of the JAK2 V617F mutation in coronary patients.
    Muendlein A; Gasser K; Kinz E; Stark N; Leiherer A; Rein P; Saely CH; Grallert H; Peters A; Drexel H; Lang AH
    Am J Hematol; 2014 Mar; 89(3):295-301. PubMed ID: 24265174
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development of a Targeted Next-Generation Sequencing Assay to Detect Diagnostically Relevant Mutations of JAK2, CALR, and MPL in Myeloproliferative Neoplasms.
    Frawley T; O'Brien CP; Conneally E; Vandenberghe E; Percy M; Langabeer SE; Haslam K
    Genet Test Mol Biomarkers; 2018 Feb; 22(2):98-103. PubMed ID: 29323541
    [TBL] [Abstract][Full Text] [Related]  

  • 59. JAK2 rs10974944 is associated with both V617F-positive and negative myeloproliferative neoplasms in a Vietnamese population: A potential genetic marker.
    Ngoc NT; Hau BB; Vuong NB; Xuan NT
    Mol Genet Genomic Med; 2022 Oct; 10(10):e2044. PubMed ID: 35996819
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Detection and Diagnostic Values of JAK2, CALR, MPL Gene Mutations in 208 Cases of BCR/ABL1 Negative Chronic Myeloproliferative Diseases].
    Li ZL; Gao L; Zhang H; Zhang CX; Chen YR; Huang FZ; Gong M; Gao YY; Tang Y; Ma YG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Aug; 26(4):1122-1128. PubMed ID: 30111418
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.